IRADIMED CORP (IRMD) Stock Fundamental Analysis
NASDAQ:IRMD - Nasdaq - US46266A1097 - Common Stock - Currency: USD
IRMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. IRMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IRMD has a decent growth rate and is not valued too expensively. This makes IRMD very considerable for quality investing!
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
In the past year IRMD had a positive cash flow from operations.
In the past 5 years IRMD has always been profitable.
IRMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IRMD has a better Return On Assets (19.45%) than 97.86% of its industry peers.
IRMD's Return On Equity of 21.97% is amongst the best of the industry. IRMD outperforms 94.12% of its industry peers.
IRMD has a better Return On Invested Capital (19.22%) than 97.86% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 7.89%.
The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.22%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.45% | ||
| ROE | 21.97% | ||
| ROIC | 19.22% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
IRMD's Profit Margin of 26.33% is amongst the best of the industry. IRMD outperforms 96.26% of its industry peers.
IRMD's Profit Margin has been stable in the last couple of years.
IRMD has a Operating Margin of 30.14%. This is amongst the best in the industry. IRMD outperforms 98.93% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
The Gross Margin of IRMD (76.91%) is better than 89.84% of its industry peers.
IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.14% | ||
| PM (TTM) | 26.33% | ||
| GM | 76.91% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
The number of shares outstanding for IRMD has been increased compared to 5 years ago.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 43.31 indicates that IRMD is not in any danger for bankruptcy at the moment.
The Altman-Z score of IRMD (43.31) is better than 99.47% of its industry peers.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 43.31 |
ROIC/WACC2.15
WACC8.93%
2.3 Liquidity
A Current Ratio of 8.87 indicates that IRMD has no problem at all paying its short term obligations.
IRMD has a Current ratio of 8.87. This is amongst the best in the industry. IRMD outperforms 90.37% of its industry peers.
A Quick Ratio of 7.62 indicates that IRMD has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.62, IRMD belongs to the best of the industry, outperforming 90.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.87 | ||
| Quick Ratio | 7.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.04% over the past year.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 11.04% in the last year.
The Revenue has been growing by 13.71% on average over the past years. This is quite good.
EPS 1Y (TTM)11.04%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.04%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%10.87%
3.2 Future
The Earnings Per Share is expected to grow by 10.91% on average over the next years. This is quite good.
Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 9.23% on average per year.
EPS Next Y7.25%
EPS Next 2Y10.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.78%
Revenue Next 2Y9.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 35.99 indicates a quite expensive valuation of IRMD.
IRMD's Price/Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 71.66% of the companies in the same industry.
IRMD's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.28.
A Price/Forward Earnings ratio of 30.32 indicates a quite expensive valuation of IRMD.
Based on the Price/Forward Earnings ratio, IRMD is valued a bit cheaper than the industry average as 71.12% of the companies are valued more expensively.
IRMD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 21.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.99 | ||
| Fwd PE | 30.32 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 70.59% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, IRMD is valued a bit cheaper than the industry average as 73.80% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.81 | ||
| EV/EBITDA | 31.26 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)4.96
PEG (5Y)2.59
EPS Next 2Y10.91%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IRMD has a Yearly Dividend Yield of 1.12%. Purely for dividend investing, there may be better candidates out there.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.82. IRMD pays more dividend than 94.65% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.42, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.12% |
5.2 History
IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
IRMD pays out 39.74% of its income as dividend. This is a sustainable payout ratio.
DP39.74%
EPS Next 2Y10.91%
EPS Next 3YN/A
61.54
+1.03 (+1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners58.77%
Inst Owner Change0.62%
Ins Owners36.8%
Ins Owner Change0.91%
Market Cap782.79M
Analysts82.5
Price Target72.42 (17.68%)
Short Float %2.96%
Short Ratio5.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.12% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.74%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.96%
Max EPS beat(2)0.43%
EPS beat(4)3
Avg EPS beat(4)5.2%
Min EPS beat(4)-1.96%
Max EPS beat(4)12.81%
EPS beat(8)6
Avg EPS beat(8)6.55%
EPS beat(12)10
Avg EPS beat(12)7.11%
EPS beat(16)14
Avg EPS beat(16)13.86%
Revenue beat(2)0
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)-0.71%
Revenue beat(4)0
Avg Revenue beat(4)-0.72%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)4
Avg Revenue beat(12)-0.25%
Revenue beat(16)7
Avg Revenue beat(16)0.78%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.99 | ||
| Fwd PE | 30.32 | ||
| P/S | 10.42 | ||
| P/FCF | 56.81 | ||
| P/OCF | 30.07 | ||
| P/B | 8.69 | ||
| P/tB | 9.02 | ||
| EV/EBITDA | 31.26 |
EPS(TTM)1.71
EY2.78%
EPS(NY)2.03
Fwd EY3.3%
FCF(TTM)1.08
FCFY1.76%
OCF(TTM)2.05
OCFY3.33%
SpS5.91
BVpS7.08
TBVpS6.82
PEG (NY)4.96
PEG (5Y)2.59
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.45% | ||
| ROE | 21.97% | ||
| ROCE | 24.29% | ||
| ROIC | 19.22% | ||
| ROICexc | 41.77% | ||
| ROICexgc | 45.2% | ||
| OM | 30.14% | ||
| PM (TTM) | 26.33% | ||
| GM | 76.91% | ||
| FCFM | 18.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexcg growth 3Y-6.9%
ROICexcg growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1559.79% | ||
| Cap/Sales | 16.31% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 111.09% | ||
| Profit Quality | 69.64% | ||
| Current Ratio | 8.87 | ||
| Quick Ratio | 7.62 | ||
| Altman-Z | 43.31 |
F-Score5
WACC8.93%
ROIC/WACC2.15
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.04%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
EPS Next Y7.25%
EPS Next 2Y10.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.04%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%10.87%
Revenue Next Year8.78%
Revenue Next 2Y9.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.94%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y96.33%
OCF growth 3Y31.53%
OCF growth 5Y20.16%